SuperworthXBiotech EPS XBIT
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Dec 31, 2021
- −$0.58
- Latest quarter, Q4 FY21
- −$0.21
- Fiscal year 2021
- −$0.58
XBiotech's earnings per share was −$0.58 over the twelve months to Dec 31, 2021.
In its latest quarter, Q4 FY21, it was −$0.21.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2021 | −$0.58 | n/a |
| FY2020 | −$0.39 | −103% |
| FY2019 | $14.35 | n/a |
| FY2018 | −$0.58 | n/a |
| FY2017 | −$0.96 | n/a |
| FY2016 | −$1.62 | n/a |
| FY2015 | −$1.21 | n/a |
| FY2014 | −$0.89 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY21 | −$0.21 | n/a | −$0.58 | |
| Q3 FY21 | −$0.11 | n/a | −$0.43 | |
| Q2 FY21 | −$0.17 | n/a | −$0.41 | |
| Q1 FY21 | −$0.09 | n/a | −$0.48 | |
| Q4 FY20 | −$0.06 | −100% | −$0.39 | |
| Q3 FY20 | −$0.09 | n/a | $14.49 | |
| Q2 FY20 | −$0.24 | n/a | $14.43 | |
| Q1 FY20 | $0.00 | n/a | $14.51 | |
| Q4 FY19 | $14.82 | n/a | $14.35 | |
| Q3 FY19 | −$0.15 | n/a | −$0.64 | |
| Q2 FY19 | −$0.16 | n/a | −$0.63 | |
| Q1 FY19 | −$0.16 | n/a | −$0.63 |
Against its peers
Companies in Drug Manufacturers - General nearest XBiotech's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| XBITXBiotech | n/m | |
| SPROSpero Therapeutics | $0.11 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| Peer median | $0.46 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on XBiotech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.